Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASH 2018 /
Ibrutinib-based therapy superior for younger patients with previously untreated CLL compared with current standard of care

1st - 4th Dec 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 04.12.18
Views: 141

Dr Tait Shanafelt - Standford University, Stanford, USA

Dr Tait Shanafelt speaks to ecancer at ASH 2018 about the efficacy of ibrutinib-based therapy for younger patients with previously untreated CLL and the comparison with the current standard of care.

He explains that the trial was designed to compare this novel treatment of ibrutinib-based therapy with FCR chemoimmunotherapy which is the current gold standard.

Dr Shanafelt reveals that there was found to be an improvement in both progression free survival and overall survival for the novel therapy.

Read more about this work here.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation